[go: up one dir, main page]

AU2003260803A1 - Sustained release pharmaceutical composition - Google Patents

Sustained release pharmaceutical composition

Info

Publication number
AU2003260803A1
AU2003260803A1 AU2003260803A AU2003260803A AU2003260803A1 AU 2003260803 A1 AU2003260803 A1 AU 2003260803A1 AU 2003260803 A AU2003260803 A AU 2003260803A AU 2003260803 A AU2003260803 A AU 2003260803A AU 2003260803 A1 AU2003260803 A1 AU 2003260803A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
sustained release
release pharmaceutical
sustained
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003260803A
Other versions
AU2003260803A8 (en
Inventor
Sampath Kumar Devarajan
Kour Chand Jindal
Rajesh Suresh Kshirsagar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orchid Pharma Ltd
Original Assignee
Orchid Chemicals and Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orchid Chemicals and Pharmaceuticals Ltd filed Critical Orchid Chemicals and Pharmaceuticals Ltd
Publication of AU2003260803A1 publication Critical patent/AU2003260803A1/en
Publication of AU2003260803A8 publication Critical patent/AU2003260803A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
AU2003260803A 2002-08-30 2003-08-29 Sustained release pharmaceutical composition Abandoned AU2003260803A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN640/MAS/2002 2002-08-30
IN640CH2002 2002-08-30
PCT/IB2003/003602 WO2004019901A2 (en) 2002-08-30 2003-08-29 Sustained release pharmaceutical composition

Publications (2)

Publication Number Publication Date
AU2003260803A1 true AU2003260803A1 (en) 2004-03-19
AU2003260803A8 AU2003260803A8 (en) 2004-03-19

Family

ID=34509340

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003260803A Abandoned AU2003260803A1 (en) 2002-08-30 2003-08-29 Sustained release pharmaceutical composition

Country Status (2)

Country Link
AU (1) AU2003260803A1 (en)
WO (1) WO2004019901A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1126826E (en) * 1998-11-02 2008-11-25 Elan Pharma Int Ltd Multiparticulate modified release composition of methylphenidate
WO2004105728A2 (en) * 2003-05-27 2004-12-09 Ranbaxy Laboratories Limited Solid dispersions of cefpodoxime proxetil and processes for their preparation
US20060233878A1 (en) * 2003-09-30 2006-10-19 Lupin Limited Extended release formulation of beta-lactam antibiotics
EA011374B1 (en) * 2004-01-06 2009-02-27 Панацея Биотек Лимитед Non-disintegrating oral solid composition of high dose of water soluble drugs
GB0400971D0 (en) * 2004-01-16 2004-02-18 Sandoz Ag Pharmaceutical compositions
EP1681050A1 (en) * 2005-01-13 2006-07-19 Strides Arcolab Limited Dispersible sustained release pharmaceutical compositions
DE102005019458A1 (en) 2005-04-25 2006-10-26 Grünenthal GmbH Composition, useful in the preparation of pellets and the multi-particular-presentation form, comprises cefuroximaxetil and carrageenan of the group of lambda carrageenan, tau carrageenan and kappa carrageenan
WO2008057058A1 (en) * 2006-11-10 2008-05-15 Nobel Ilac Sanayii Ve Ticaret As Oral pharmaceutical compositions
EP2094080B1 (en) * 2006-11-13 2017-06-07 Basf Se Utilisation of block copolymers based on vinyl lactames and vinyl acetate as solubilisers
CN102028669A (en) * 2010-10-27 2011-04-27 北京华禧联合科技发展有限公司 Slow release preparation of cefcapene pivoxil hydrochloride and preparation method thereof
WO2013109202A2 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic Pharmaceutical compounds comprising cefetamet
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140274990A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
EP3043797B1 (en) 2013-09-09 2020-04-08 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
MX2017007287A (en) * 2014-12-01 2017-08-25 Sun Pharmaceutical Ind Ltd Extended-release cefpodoxime proxetil composition.
CN104434875B (en) * 2014-12-26 2017-08-01 华北制药河北华民药业有限责任公司 A kind of Cefaclor Capsules and preparation method thereof
CN107569466A (en) * 2017-09-17 2018-01-12 石家庄四药有限公司 Cefuroxime axetil pharmaceutical composition prepared by a kind of direct compression method
CN112023032B (en) * 2020-09-14 2022-03-18 广东鼎信医药科技有限公司 Pharmaceutical composition containing digestive enzyme and preparation method thereof
CN113908133B (en) * 2021-11-29 2023-11-03 河南省儿童医院郑州儿童医院 Cefixime sustained release tablet and preparation method thereof
WO2025046044A1 (en) * 2023-09-01 2025-03-06 F. Hoffmann-La Roche Ag Novel methods for preparing semi-solid compositions and uses thereof
CN117243913B (en) * 2023-10-24 2024-09-17 国药集团致君(深圳)制药有限公司 Cefaclor sustained-release composition and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2742989B1 (en) * 1995-12-29 1998-01-23 Adir BIOADHESIVE PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS
AT413647B (en) * 1998-11-26 2006-04-15 Sandoz Ag USE OF A COPOLYMERISATE OF 1-VINYL-2-PYRROLIDONE AND VINYL ACETATE FOR THE PREPARATION OF CEFUROXIMAXETIL-SUBJECTED TABLETS
WO2001000177A1 (en) * 1999-06-29 2001-01-04 Micio Pharma Chemical Aktiengesellschaft Retard formulation of amoxicillin for oral administration

Also Published As

Publication number Publication date
WO2004019901A3 (en) 2005-05-06
AU2003260803A8 (en) 2004-03-19
WO2004019901A2 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
AU2003291103A1 (en) Pharmaceutical composition
AU2003262059A1 (en) Sustained release preparation
AU2009201465A1 (en) Pharmaceutical Compositions with Improved Dissolution
AU2003278393A1 (en) New use for pharmaceutical composition
EP1469840A4 (en) Cyclosporin-containing sustained release pharmaceutical composition
AUPR602501A0 (en) Sustained release pharmaceutical composition
AU2003215334A1 (en) Inhalable formulations for sustained release
AU2003260803A1 (en) Sustained release pharmaceutical composition
AU2002337803A1 (en) Sustained release pharmaceutical compositions
AU2003250372A1 (en) Pharmaceutical composition
AU2002364468A1 (en) Solid orally-dispersible pharmaceutical formulation
PL376840A1 (en) Prolonged release pharmaceutical composition
AU2003241671A1 (en) Controlled-release drug composition
AU2001248772A1 (en) Sustained release drug compositions
EP1478353A4 (en) Sustained release pharmaceutical composition
AU2003267231A1 (en) Pharmaceutical compositions with improved dissolution
AU2003284460A1 (en) Medicinal composition
AU2003291642A1 (en) Pyrazoloazepine compounds as pharmaceutical agents
AU2003216503A1 (en) Stable pharmaceutical compositions
AU2003208621A1 (en) A pharmaceutical composition
AU2003280799A1 (en) Medicinal composition
AU2003280678A1 (en) Medicinal composition
AU2003303591A1 (en) Pharmaceutical compositions with improved dissolution
AUPS188302A0 (en) Pharmaceutical composition
AU2002236132A1 (en) Modified release oral pharmaceutical composition

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase